[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Reddy AT: Advances in biology and treatment of childhood brain tumors. Curr Neurol Neurosci Rep; 2001 Mar;1(2):137-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in biology and treatment of childhood brain tumors.
  • Childhood brain tumors are collectively the most common solid neoplasm and the leading cause of cancer-related death in children.
  • A growing body of work is aimed at improving the outcome for children with brain tumors not only through clinical trials, but also by focusing on the biologic underpinning of these diseases that have been poorly understood.
  • [MeSH-major] Brain Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Damage, Chronic / etiology. Brain Stem. Chemotherapy, Adjuvant. Child. Child, Preschool. Clinical Trials as Topic. Cranial Irradiation. Craniotomy. Diagnostic Imaging. Disease-Free Survival. Ependymoma / drug therapy. Ependymoma / mortality. Ependymoma / radiotherapy. Ependymoma / surgery. Germinoma / drug therapy. Germinoma / mortality. Germinoma / radiotherapy. Germinoma / surgery. Glioma / drug therapy. Glioma / mortality. Glioma / radiotherapy. Glioma / surgery. Humans. Infant. Medulloblastoma / drug therapy. Medulloblastoma / mortality. Medulloblastoma / radiotherapy. Medulloblastoma / surgery. Neuroectodermal Tumors / drug therapy. Neuroectodermal Tumors / mortality. Neuroectodermal Tumors / radiotherapy. Neuroectodermal Tumors / surgery. Palliative Care. Radiosurgery. Radiotherapy, Adjuvant. Supratentorial Neoplasms / drug therapy. Supratentorial Neoplasms / mortality. Supratentorial Neoplasms / radiotherapy. Supratentorial Neoplasms / surgery. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 1997 Jan 15;17(2):530-42 [8987776.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):6-14 [2354409.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11519-24 [10500209.001]
  • [Cites] J Neurosurg. 1997 May;86(5):747-54 [9126887.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4C):3569-74 [10629654.001]
  • [Cites] J Neurooncol. 1999 Aug;44(1):71-6 [10582672.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):870-5 [10679657.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1117-26 [10613303.001]
  • [Cites] J Neurooncol. 1993 Feb;15(2):125-31 [8509817.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):229-45 [8270446.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1246-53 [10715294.001]
  • [Cites] Neurosurg Clin N Am. 1990 Jan;1(1):37-48 [2135972.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):555-62 [8630965.001]
  • [Cites] Gene Ther. 2000 May;7(10):867-74 [10845725.001]
  • [Cites] J Neurooncol. 1999;45(1):61-7 [10728911.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):249-54 [10659011.001]
  • [Cites] J Neurooncol. 1992 Jul;13(3):283-90 [1517804.001]
  • [Cites] J Neurosurg. 1989 Jun;70(6):853-61 [2715812.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95 [10661334.001]
  • [Cites] J Biol Chem. 2000 Jan 7;275(1):565-70 [10617652.001]
  • [Cites] Cancer. 1985 Oct 1;56(7):1497-501 [4040799.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Dec;115(2):96-9 [10598140.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12867-71 [7809137.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):557-63 [2364367.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):137-45 [10477017.001]
  • [Cites] J Neurooncol. 1997 May;32(3):235-41 [9049885.001]
  • [Cites] J Neurooncol. 1999 Aug;44(1):77-83 [10582673.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):685-92 [10649264.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2127-36 [10561268.001]
  • [Cites] Childs Nerv Syst. 1998 Oct;14(10):596-601 [9840386.001]
  • [Cites] J Neurosurg. 1997 Jun;86(6):943-9 [9171172.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):690-8 [7931615.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1292-7; discussion 1297-8 [10598695.001]
  • [Cites] J Neurooncol. 1999 Sep;44(2):181-5 [10619503.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):711-9 [9973222.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):419-26 [9308946.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1171-6 [10725628.001]
  • [Cites] Neurosurgery. 1995 Oct;37(4):655-66; discussion 666-7 [8559293.001]
  • [Cites] Br J Cancer. 1999 Dec;81(7):1150-4 [10584875.001]
  • [Cites] Cancer. 2000 May 1;88(9):2189-93 [10813733.001]
  • (PMID = 11898509.001).
  • [ISSN] 1528-4042
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


2. Yanofsky RA, Seshia SS, Dawson AJ, Stobart K, Greenberg CR, Booth FA, Prasad C, Del Bigio MR, Wrogemann JJ, Fike F, Gatti RA: Ataxia-telangiectasia: atypical presentation and toxicity of cancer treatment. Can J Neurol Sci; 2009 Jul;36(4):462-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The onset of progressive cerebellar ataxia in early childhood is considered a key feature of ataxia-telangiectasia (A-T), accompanied by ocular apraxia, telangiectasias, immunodeficiency, cancer susceptibility and hypersensitivity to ionizing radiation.
  • The two children who received cranial irradiation developed supratentorial primitive neuroectodermal tumors of the brain, an association not previously described, with fatal outcomes.
  • Radiation therapy and radiomimetic drugs should be avoided in individuals with A-T.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Ataxia Telangiectasia / chemically induced. Ataxia Telangiectasia / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Ataxia Telangiectasia Mutated Proteins. Cell Cycle Proteins / metabolism. Child. Child, Preschool. DNA-Binding Proteins / metabolism. Humans. Magnetic Resonance Imaging. Male. Nerve Tissue Proteins / metabolism. Protein-Serine-Threonine Kinases / metabolism. Retrospective Studies. Tumor Suppressor Proteins / metabolism. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Ataxia.
  • Genetic Alliance. consumer health - Ataxia Telangiectasia.
  • MedlinePlus Health Information. consumer health - Ataxia Telangiectasia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650357.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI 067769; United States / NINDS NIH HHS / NS / NS 052528
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nerve Tissue Proteins; 0 / Tumor Suppressor Proteins; 0 / alpha-Fetoproteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


3. Lindsey JC, Lusher ME, Strathdee G, Brown R, Gilbertson RJ, Bailey S, Ellison DW, Clifford SC: Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. Int J Cancer; 2006 Jan 15;118(2):346-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Methylation-dependent transcriptional silencing of MCJ has been observed in ovarian cancers and associated with increased resistance to chemotherapeutic agents; however, its role in other cancer types has not been widely investigated.
  • We examined the status of MCJ in intracranial primitive neuroectodermal tumours [PNETs, comprising cerebellar PNETs (medulloblastomas) and supratentorial PNETs (stPNETs)] and ependymomas, together representing the most common malignant brain tumours of childhood.
  • [MeSH-major] Brain Neoplasms / genetics. Ependymoma / genetics. Epigenesis, Genetic. HSP40 Heat-Shock Proteins / biosynthesis. Membrane Proteins / biosynthesis. Neuroectodermal Tumors, Primitive / genetics
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor. Child. Child, Preschool. DNA Methylation. Female. Gene Expression Profiling. Gene Silencing. Humans. Male. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16049974.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNAJC1 protein, human; 0 / HSP40 Heat-Shock Proteins; 0 / Membrane Proteins
  •  go-up   go-down


Advertisement
4. Oberfield SE, Garvin JH Jr: Thalamic and hypothalamic tumors of childhood: endocrine late effects. Pediatr Neurosurg; 2000 May;32(5):264-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalamic and hypothalamic tumors of childhood: endocrine late effects.
  • Children who have received chemotherapy and radiation therapy for treatment of thalamic/hypothalamic tumors are at risk for late effects, specifically endocrine dysfunction.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Endocrine System Diseases / etiology. Radiation Injuries / etiology. Supratentorial Neoplasms / drug therapy. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adrenal Insufficiency / etiology. Body Height / radiation effects. Child. Child, Preschool. Dose-Response Relationship, Radiation. Female. Growth Disorders / etiology. Growth Hormone / deficiency. Hormone Replacement Therapy. Humans. Hyperlipidemias / etiology. Hypothalamic Neoplasms / drug therapy. Hypothalamic Neoplasms / radiotherapy. Hypothyroidism / etiology. Infant. Male. Puberty, Precocious / etiology. Radiotherapy, Adjuvant / adverse effects

  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel.
  • (PMID = 10965274.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  • [Number-of-references] 24
  •  go-up   go-down


5. Didiano D, Shalaby T, Lang D, Grotzer MA: Telomere maintenance in childhood primitive neuroectodermal brain tumors. Neuro Oncol; 2004 Jan;6(1):1-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere maintenance in childhood primitive neuroectodermal brain tumors.
  • Primitive neuroectodermal tumors (PNETs), including medulloblastoma (PNET/MB) and supratentorial PNET (sPNET), are the most common malignant brain tumors of childhood.
  • Inhibition of telomerase function represents a novel experimental therapeutic strategy in childhood PNETs that warrants further investigation.
  • [MeSH-major] Brain Neoplasms / enzymology. Catechin / analogs & derivatives. Neuroectodermal Tumors, Primitive / enzymology. Telomere / enzymology
  • [MeSH-minor] Adolescent. Adult. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / physiology. Child. Child, Preschool. DNA-Binding Proteins. Dose-Response Relationship, Drug. Female. Fetus. Humans. Infant. Male. Middle Aged. Telomerase / antagonists & inhibitors. Telomerase / biosynthesis. Telomerase / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pharm Res. 2002 Feb;25(1):93-101 [11885700.001]
  • [Cites] Mutat Res. 1999 Jul 16;428(1-2):339-44 [10518005.001]
  • [Cites] Childs Nerv Syst. 2002 Apr;18(3-4):112-7 [11981616.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4434-8 [12154051.001]
  • [Cites] Biol Pharm Bull. 2002 Sep;25(9):1238-40 [12230128.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):879-84 [12415258.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3882-90 [12458198.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):824-30 [12591733.001]
  • [Cites] Nature. 1991 Apr 18;350(6319):569-73 [1708110.001]
  • [Cites] J Natl Cancer Inst. 1993 Jul 7;85(13):1038-49 [8515490.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Science. 1995 Sep 1;269(5228):1236-41 [7544491.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jun;4(4):393-9 [7655336.001]
  • [Cites] EMBO J. 1995 Sep 1;14(17):4240-8 [7556065.001]
  • [Cites] Lancet. 1995 Nov 11;346(8985):1267-8 [7475720.001]
  • [Cites] Mol Cell Biol. 1996 Jan;16(1):53-65 [8524329.001]
  • [Cites] Adv Exp Med Biol. 1996;401:51-61 [8886126.001]
  • [Cites] Genome Res. 1996 Oct;6(10):986-94 [8908518.001]
  • [Cites] Hum Pathol. 1997 Apr;28(4):416-20 [9104940.001]
  • [Cites] Am J Clin Pathol. 1997 May;107(5):548-54 [9128267.001]
  • [Cites] Jpn J Cancer Res. 1997 Jun;88(6):553-8 [9263532.001]
  • [Cites] Eur J Cancer. 1997 Apr;33(5):787-91 [9282118.001]
  • [Cites] J Med Chem. 1999 Nov 4;42(22):4538-46 [10579817.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Invest Dermatol. 2000 Feb;114(2):259-67 [10651984.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):452-9 [10690523.001]
  • [Cites] J Neurosurg. 2000 May;92(5):832-40 [10794298.001]
  • [Cites] Anticancer Res. 2000 Jul-Aug;20(4):2659-64 [10953340.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] Oncogene. 2000 Sep 21;19(40):4604-10 [11030149.001]
  • [Cites] Trends Biotechnol. 2001 Mar;19(3):114-20 [11179805.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2425-33 [11489822.001]
  • [Cites] Mutat Res. 2001 Sep 1;480-481:299-304 [11506822.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2064-72 [11597385.001]
  • [Cites] Eur J Cancer. 2002 Jan;38(1):83-91 [11750844.001]
  • [Cites] Methods. 2001 Dec;25(4):386-401 [11846608.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):598-610 [11850785.001]
  • [Cites] J Nutr Sci Vitaminol (Tokyo). 1997 Dec;43(6):679-84 [9530620.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2117-25 [9605755.001]
  • [Cites] Br J Cancer. 1998 May;77(10):1633-7 [9635839.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 19;249(2):391-6 [9712707.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5406-10 [9850072.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):381 [10201368.001]
  • [Cites] Proc Soc Exp Biol Med. 1999 Apr;220(4):225-8 [10202393.001]
  • [Cites] Curr Opin Cell Biol. 1999 Jun;11(3):318-24 [10395557.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4004-11 [10463599.001]
  • [Cites] Biochemistry. 1999 Aug 31;38(35):11501-7 [10471302.001]
  • [Cites] Bioorg Med Chem Lett. 1999 Sep 6;9(17):2463-8 [10498189.001]
  • [Cites] Cell Res. 2002 Mar;12(1):1-7 [11942406.001]
  • (PMID = 14769133.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC1871965
  •  go-up   go-down


6. Timmermann B, Kortmann RD, Kühl J, Meisner C, Dieckmann K, Pietsch T, Bamberg M: Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. J Clin Oncol; 2002 Feb 01;20(3):842-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91.
  • PURPOSE: To evaluate the outcome of children with supratentorial primitive neuroectodermal tumors after surgery, irradiation, and chemotherapy and to identify factors predictive for survival.
  • Irradiation volume was recommended to encompass the neuraxis with 35.2-Gy total dose followed by a boost (20.0 Gy) to the primary tumor site (n = 54).
  • Seven patients were irradiated to the tumor region only with a total dose of 54.0 Gy.
  • There was a positive trend in outcome for nonmetastatic and pineal tumors.
  • Volume of irradiation should encompass the whole CNS with additional boost to the tumor region.
  • [MeSH-major] Neuroectodermal Tumors / radiotherapy. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Lomustine / administration & dosage. Male. Methotrexate / administration & dosage. Neoplasm Recurrence, Local. Radiotherapy Dosage. Survival Rate. Treatment Outcome. Vincristine / administration & dosage


7. Keene DL, Johnston DL, Grimard L, Michaud J, Vassilyadi M, Ventureyra E: Vascular complications of cranial radiation. Childs Nerv Syst; 2006 Jun;22(6):547-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hundred and 13 cases involved tumors of the central nervous system.
  • Post radiation cerebral vascular disease occurred in 11 (5%) patients, and all but one patient had a tumor involving the central nervous system (mainly in the posterior fossa and supratentorial midline).
  • CONCLUSION: There is an increased risk of cerebral vascular disease after radiation therapy in childhood, especially in children who received high dose radiation at the posterior fossa and supratentorial axial region.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Drug-Related Side Effects and Adverse Reactions. Vascular Diseases / etiology






Advertisement